Van ECK Associates Corp Reduces Position in AbbVie Inc. $ABBV

Van ECK Associates Corp trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 24.5% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 195,741 shares of the company’s stock after selling 63,613 shares during the quarter. Van ECK Associates Corp’s holdings in AbbVie were worth $49,256,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Ferguson Wellman Capital Management Inc. grew its stake in shares of AbbVie by 1.0% in the second quarter. Ferguson Wellman Capital Management Inc. now owns 656,778 shares of the company’s stock worth $165,272,000 after acquiring an additional 6,367 shares during the period. Nissay Asset Management Corp Japan boosted its holdings in AbbVie by 14.9% in the second quarter. Nissay Asset Management Corp Japan now owns 568,521 shares of the company’s stock worth $143,063,000 after purchasing an additional 73,696 shares during the last quarter. Braun Stacey Associates Inc. boosted its holdings in AbbVie by 3.9% in the second quarter. Braun Stacey Associates Inc. now owns 87,528 shares of the company’s stock worth $22,026,000 after purchasing an additional 3,269 shares during the last quarter. Chapin Davis Inc. raised its stake in AbbVie by 10.5% during the 2nd quarter. Chapin Davis Inc. now owns 15,763 shares of the company’s stock valued at $3,967,000 after buying an additional 1,500 shares during the last quarter. Finally, Navellier & Associates Inc. raised its stake in AbbVie by 1.0% during the 2nd quarter. Navellier & Associates Inc. now owns 28,575 shares of the company’s stock valued at $7,191,000 after buying an additional 270 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 0.1%

Shares of NYSE:ABBV opened at $256.27 on Monday. The stock has a 50 day moving average of $254.66 and a 200 day moving average of $230.05. The company has a market cap of $452.78 billion, a PE ratio of 72.39, a price-to-earnings-growth ratio of 1.16 and a beta of 0.29. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter last year, the business earned $2.97 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s payout ratio is 195.48%.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case.
• Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics
• Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth.

Analysts Set New Price Targets

ABBV has been the topic of a number of research reports. Piper Sandler raised their price target on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Guggenheim raised their target price on AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Morgan Stanley restated an “overweight” rating and set a $296.00 price target on shares of AbbVie in a research note on Monday, August 3rd. Canaccord Genuity Group upped their price target on shares of AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Finally, UBS Group increased their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $275.95.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.